Zscaler to Post Q3 Earnings: Time to Buy, Sell or Hold the Stock?
Zscaler ZS is scheduled to report its third-quarter fiscal 2025 results on May 29, 2025.
Zscaler anticipates revenues between $665 million and $667 million for third-quarter fiscal 2025. The Zacks Consensus Estimate for ZS' fiscal third-quarter revenues is pegged at $666.1 million, indicating year-over-year growth of 20.4%.
For the fiscal third quarter, the company expects non-GAAP earnings per share in the band of 75-76 cents. The Zacks Consensus Estimate for ZS' fiscal third-quarter earnings is pegged at 75 cents per share, which remained unchanged over the past 60 days and indicates a year-over-year decline of 14.8%.
Zscaler's earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 24.55%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Zscaler, Inc. Price and EPS Surprise
Zscaler, Inc. price-eps-surprise | Zscaler, Inc. Quote
Earnings Whispers for Zscaler
Our proven model does not conclusively predict an earnings beat for Zscaler this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here. You can see the complete list of today's Zacks #1 Rank stocks here.
Though Zscaler currently carries a Zacks Rank #3, it has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Factors to Note for Zscaler's Q3 Results
Zscaler's third-quarter results are expected to show sustained demand for its security and networking solutions, given the persistent expansion of the global security space. The adoption of ZS' in-cloud security solution, Zero Trust Exchange, driven by the ongoing digital transformation across organizations and the growing popularity of hybrid work, is likely to have been a key catalyst.
The growing adoption of Software-Defined Wide Area Network (SD-WAN) solutions might have acted as a primary driver in the fiscal third quarter. Per the latest Future Market Insights report, the market size for SD-WAN solutions and products is expected to reach $80.91 billion by 2034 from $5.36 billion in 2024, witnessing a CAGR of 31.6%. As only a select number of vendors offer security and SD-WAN solutions, Zscaler has been gaining from the increasing opportunities in this space. The company's partnerships with VMware and Silver Peak have enabled it to secure SD-WAN deliveries. This is expected to have aided Zscaler's fiscal third-quarter performance.
ZS' existing core products, mainly the Zscaler Internet Access and Zscaler Private Access, have been driving customer retention. The addition of new features to its Zero Trust Exchange, such as Cloud Access Security Broker, Cloud Browser Isolation, Cloud Protection, Zscaler Digital Experience and Cloud Security Posture Management for software-as-a-service applications, is expected to have driven its product portfolio expansion and customer acquisition. Generative AI and Agentic AI are also acting as a growth pillar for Zscaler. The company now serves 14 out of 15 U.S. cabinet-level agencies. This is likely to have provided stability to Zscaler's top line in the to-be-reported quarter.
Our model estimates for third-quarter revenues from Channel Partners and Direct Customers are pegged at $588 million and $77.4 million, respectively. We expect the remaining performance obligation at the end of the quarter to be approximately $4.65 billion.
However, as customers scrutinize large deals more closely, with continued tight IT budgets, Zscaler faces longer deal cycles. To counter this, Zscaler is growing investments to improve sales and marketing (S&M) capabilities and higher research and development (R&D) costs, which might have weighed on the company's fiscal third-quarter bottom line.
ZS Price Performance & Stock Valuation
Zscaler's shares have gained 40.9% year to date, outperforming the Zacks Security industry's growth of 16.9%. The stock has also outperformed its peers in the cloud-based security solution space, such as Palo Alto Networks PANW, CrowdStrike Holdings CRWD and CyberArk Software CYBR, which have risen 2.7%, 33.2% and 14.5%, respectively, in the same time frame.
Now, let's look at the value Zscaler offers investors at the current levels. ZS stock is trading at a discount with a forward 12-month P/S of 12.79X compared with the industry's 14.21X, reflecting an undervaluation.
Investment Thesis for Zscaler
Zscaler is benefiting from the rising demand for cybersecurity solutions due to the slew of data breaches. The increasing demand for privileged access security in digital transformation and cloud migration strategies is a key growth driver.
A strong presence across verticals, such as banking, insurance, healthcare, public sector, pharmaceuticals, telecommunications services and education, safeguards it from the negative impacts of ongoing macroeconomic headwinds. Portfolio expansion through acquisitions like Avalor, Canonic Security and ShiftRight is praiseworthy.
However, Zscaler faces intense competition from other established cybersecurity players, including Palo Alto Networks, CyberArk and CrowdStrike. Zscaler Internet Access and Private Access face competition from Palo Alto Networks Prisma Access, Prisma SD-WAN, CrowdStrike Falcon Zero Trust, CyberArk Secure Web Sessions and CYBR Identity Security Platform.
To survive in the highly competitive cybersecurity market, Zscaler is continuously investing in broadening its capabilities. Over the past few years, Zscaler has invested heavily to enhance its S&M capabilities, particularly by increasing the sales force. Unfortunately, its aggressive investment in S&M and R&D might weigh on its near-term profitability.
Conclusion: Hold ZS Stock for Now
While the long-term prospects for the company remain bright, the near-term challenges associated with its profit growth warrant caution.
Therefore, we believe that it's prudent to avoid making new investments in the stock for now. For existing shareholders, holding on to Zscaler stock is the best course of action, as the long-term growth drivers are still firmly in place.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Palo Alto Networks, Inc. (PANW): Free Stock Analysis Report
CyberArk Software Ltd. (CYBR): Free Stock Analysis Report
Zscaler, Inc. (ZS): Free Stock Analysis Report
CrowdStrike (CRWD): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
11 minutes ago
- Globe and Mail
The eye of the storm isn't the end of Trump's chaos
It is comforting, in times of chaos, to believe that things will return to normal. People tend to seize on hints that the worst is over. This is why stock markets surge every time U.S. President Donald Trump does something marginally reasonable. Reality check: while moments of peace offer welcome breathing space, they are no reason to ignore the bigger picture. Canada sustained a series of body-blows in March and April, as Mr. Trump repeatedly raised annexation and levied punitive tariffs. Although the current situation may seem calmer, that is only by comparison to chaos. The country still faces serious economic threats from south of the border. Letting down the national guard now would be to fall victim to 'normalcy bias.' This theory holds that people believe during abnormal times that normality will reassert itself, removing the urgency to act. A common internet meme illustrates this with a picture of a dog surrounded by flames and saying, 'this is fine.' Last week offers strong evidence all is not fine. On Tuesday, Mr. Trump made another attempt to strong-arm Canada into joining his dream of a continental missile defence system. On Wednesday, a court ruled the U.S. president had acted beyond his authority to levy many of his tariffs. Then, one day later, another court paused the effect of that ruling, pending an appeal. Then on Friday, Mr. Trump announced that he would double tariffs on steel and aluminum. These head-spinning twists are now a feature of U.S. politics and are another reminder of the need for Canada to pivot away from the United States. On an individual level, Canadians realize this. They are boycotting American travel and making a point to buy local products. They applauded as provincial liquor retailers removed U.S. wine and spirits. They fly the Maple Leaf everywhere and dream, even more than most years, about the Stanley Cup coming home to Canada. Politicians seem to grasp it as well. The recent election campaign was consumed with the question of how best to protect Canadian independence. Prime Minister Mark Carney told the House of Commons last week that it is 'the top priority of Canada's new government to establish a new economic and security relationship with the United States and to strengthen our collaboration with reliable trading partners and allies around the world.' Mr. Carney is also pledging quick action to break down internal trade barriers, promising 'free trade across the nation' by July 1, and is seeking to join a European rearmament plan. These are positive developments. However, big decisions remain. Where to find the money to meet NATO's coming goal of defence spending equal to 5 per cent of GDP, and how best to allocate it so the country can face new threats. How to help the economy reorient more globally, instead of relying on proximity to the U.S. How to manage regional tensions that hurt Canada's ability to project a united front. None of this will be easy. It will require the country to make the hard choices to chart a new course, one that will take years or decades to emerge fully. Sacrifices will be necessary to ensure Canada remains strong and free. It will be harder to find the will to make those sacrifices if Mr. Trump's threats fade into background noise. Normalcy bias could lead Canadians to ignore his erratic behaviour. To be clear, it is not normal for a modern U.S. President to threaten to seize land from other countries. Pete Hoekstra, the U.S. ambassador to Ottawa, believes Canadians should just get over it, that the idea of annexation is dead. The diplomat clearly does not speak for his boss and is being massively disingenuous when he says that Americans are insulted by Canada's reaction to Mr. Trump's threats. And those threats continue. The President said again last week that Canada could avoid paying to join a continental missile defence program by becoming a U.S. state. Ludicrously, he claimed on social media that Ottawa is 'considering the offer.' Canadian ambassador to the United Nations Bob Rae rightly pointed out that, 'in another context this would be called a 'protection racket.'' Mr. Trump's threats will ebb and flow. Some days they will feel like a klaxon-blaring emergency while other days it will almost be possible to tune them out. But normalcy won't return on its own. Canadians have to make that happen, by keeping their elbows up and building a stronger country.
Globe and Mail
11 minutes ago
- Globe and Mail
France's Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion
France's Sanofi SNY-Q has agreed to buy U.S.-based Blueprint Medicines Corporation BPMC-Q for up to US$9.5-billion to boost its position in rare immunology diseases, in the biggest deal struck by a European health care company so far this year, according to LSEG data. Blueprint is a specialist in treatments for systemic mastocytosis, a rare blood disorder. The two companies said on Monday that Sanofi would initially pay US$129.00 per share in cash, or around US$9.1-billion. Blueprint shares jumped 27 per cent to US$128.74 in premarket trade. Sanofi stock was down about 1 per cent. Sanofi has ramped up research and development spending in recent years, prompting the company to abandon its long-term profit margin targets two years ago, as it seeks to build on the success of its blockbuster drug Dupixent for eczema and other conditions. However, it suffered a setback last week after an experimental drug for patients with a lung condition commonly called 'smoker's lung' failed a late-stage trial. The Blueprint acquisition 'represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company,' said Sanofi CEO Paul Hudson. The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit, also known as Ayvakyt, approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit is the only approved medicine for advanced and indolent systemic mastocytosis, a rare blood disorder that occurs when the body makes abnormal mast cells – a type of white blood cell. It triggers a continuous allergic response. The acquisition would also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. The deal makes 'strategic and financial sense,' said JP Morgan analysts in a note, noting that Blueprint expects Ayvakit to reach annual sales of around $2-billion by fiscal year 2030. 'We see the transaction as a good fit for Sanofi at a sensible valuation, which investors should see as a positive with time,' they added. It is the latest in a series of deals by Sanofi. Last month, it announced the US$470-million purchase of Vigil Neuroscience and in January, 2024, it struck a US$2.2-billion deal for U.S biotech firm Inhibrx. Hudson said the deal complemented Sanofi's recent acquisitions of other early-stage medicines and added that it still retained a sizable capacity for further deals. The company has said it plans to invest at least US$20-billion in the United States through 2030 to boost manufacturing and research, joining other drugmakers in responding to President Donald Trump's drive to boost local manufacturing. Besides US$129.00 per share in cash, Blueprint shareholders would also receive one non-tradeable contingent value right (CVR) per share, which would entitle the holder to receive two potential milestone payments of US$2 and US$4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, is US$9.5-billion on a fully diluted basis. It is expected to close in the third quarter, pending regulatory and shareholder approvals.
Globe and Mail
11 minutes ago
- Globe and Mail
Why Apple can make iPhones only in China, and what Canada can learn from that
John Turley-Ewart is a contributing columnist for The Globe and Mail, a regulatory compliance consultant and a Canadian banking historian. Why can't Apple AAPL-Q make iPhones in the United States, or Canada for that matter? It's a relevant question following the recent demand from U.S. President Donald Trump that Apple iPhones sold in the U.S. be made in U.S., or face a 25-per-cent tariff. The answer, that Apple can only produce its iPhones in China, and why, is a guiding truth that should inform the federal government's Throne Speech promise to 'embark on the largest transformation of its economy since the Second World War.' That truth is made plain in the remarkable book Apple in China, written by Canadian-born business journalist Patrick McGee. It reveals in disturbing detail the 'Chinafication' of high-tech manufacturing founded on Apple know-how, billions in direct investment from Apple over the last quarter-century and Beijing's belief that 'Without a strong manufacturing industry, there will be no country and no nation.' The result is a low-cost manufacturing sector underwritten by the power of an authoritarian state that delivers a sophisticated and expanding managerial and engineering class atop a scalable, just-in-time, low-wage, low-skilled, low-rights, 300 million-plus floating work force that moves as needed from factory to factory that could not (and should not) be reproduced anywhere else in the world. Trump threatens 50% tariff on EU, 25% levy on Apple for iPhones not made in U.S. Apple has few incentives to start making iPhones in U.S., despite Trump's trade war with China As Mr. McGee observed in a U.S. podcast on his book, not only do Americans not want these factory jobs, neither do the Chinese people. These jobs are sustained by the policies of Beijing's Communist leadership that lets Apple exploit the desperation of millions of people from rural China as a means of exploiting Apple itself. In 1999 Apple didn't produce its products in China. A decade later it was making almost everything there. Since 2008 Apple has trained 28 million people in China. 'This rapid consolidation,' said Mr. McGee, 'reflects a transfer of technology and know-how so consequential as to constitute a geopolitical event, like the fall of the Berlin Wall.' Apple seeded China's production capacity through astonishing investments – reaching US$55-billion annually by 2015. This supplied the capital and expertise needed to train managers and engineers to establish and run factories and complex tooling companies while encouraging raw material extraction and refining essential to feeding the just-in-time high-tech supply chain Apple products rely on to generate $US90 billion-plus in annual profits. By Mr. McGee's calculations, that US$55-billion a year is double what was invested through the U.S. Marshall Plan in today's dollars after the Second World War to rebuild 16 European countries. What we learn from Mr. McGee's research is that Apple's iPhone and other products are possible because of a unique mix of management expertise delivered across multiple industries wedded to the availability of millions of low-skill, exploitable workers. What we also learn, which is pertinent to Canada, is how management education can play a key role in transforming an economy. One reason we can't get things done in Canada – improve productivity, take full advantage of the intellectual property we create, retain our promising start-ups, attract foreign direct investment, build infrastructure on time and near budget – is that Canadians are not great managers, especially in the small and medium-sized business sectors. It is a hard truth. Perhaps Canadians know this subconsciously and it is why many in the last federal election took comfort electing a prime minister with a reputation as an outstanding manager. The 'quality of management at Canada's manufacturing firms is … well behind the United States,' according to the OECD. The OECD goes on to say that 'managers in Canada tend to have comparatively lower levels of formal education than in other countries, which may mean shortfalls in competencies, such as strategic planning, financial management, and human resources management.' Canada produces large swaths of university and college graduates in science, technology, engineering, mathematics (STEM) and the arts. Most graduate without ever taking a course in financial or business management. If Prime Minister Mark Carney's Liberal government truly wants to transform the Canadian economy, part of that long-term process must include working with businesses to invest heavily in management training while requiring the inclusion of business training in STEM and arts programs offered by colleges and universities. The U.S., through Apple, could teach engineers and managers in China how to create and lead the businesses needed to make an iPhone even if they couldn't produce it in the United States. If Apple was a Canadian company, it would have been sold or insolvent long ago.
